NO20091099L - Zabicykloforbindelser som inhibitorer av monoamingjenopptakelse - Google Patents

Zabicykloforbindelser som inhibitorer av monoamingjenopptakelse

Info

Publication number
NO20091099L
NO20091099L NO20091099A NO20091099A NO20091099L NO 20091099 L NO20091099 L NO 20091099L NO 20091099 A NO20091099 A NO 20091099A NO 20091099 A NO20091099 A NO 20091099A NO 20091099 L NO20091099 L NO 20091099L
Authority
NO
Norway
Prior art keywords
group
zabicyclo
inhibitors
compounds
monoamine reuptake
Prior art date
Application number
NO20091099A
Other languages
English (en)
Norwegian (no)
Inventor
Romano Di Fabio
Silvia Terreni
Fabrizio Micheli
Barbara Bertani
Giovanni Tedesco
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0617863A external-priority patent/GB0617863D0/en
Priority claimed from GB0617868A external-priority patent/GB0617868D0/en
Priority claimed from GB0716371A external-priority patent/GB0716371D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20091099L publication Critical patent/NO20091099L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
NO20091099A 2006-09-11 2009-03-13 Zabicykloforbindelser som inhibitorer av monoamingjenopptakelse NO20091099L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0617863A GB0617863D0 (en) 2006-09-11 2006-09-11 Chemical compounds
GB0617868A GB0617868D0 (en) 2006-09-11 2006-09-11 Chemical compounds
GB0716371A GB0716371D0 (en) 2007-08-22 2007-08-22 Chemical compounds
PCT/EP2007/059381 WO2008031772A1 (en) 2006-09-11 2007-09-07 Azabicyclic compounds as inhibitors of monoamines reuptake

Publications (1)

Publication Number Publication Date
NO20091099L true NO20091099L (no) 2009-04-03

Family

ID=38561834

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091099A NO20091099L (no) 2006-09-11 2009-03-13 Zabicykloforbindelser som inhibitorer av monoamingjenopptakelse

Country Status (19)

Country Link
US (2) US20100035914A1 (es)
EP (1) EP2064186A1 (es)
JP (1) JP4448198B2 (es)
KR (1) KR20090064447A (es)
AR (1) AR062737A1 (es)
AU (1) AU2007296301A1 (es)
BR (1) BRPI0716532A2 (es)
CA (1) CA2662538A1 (es)
CL (1) CL2007002619A1 (es)
CO (1) CO6150149A2 (es)
CR (1) CR10671A (es)
EA (1) EA200970266A1 (es)
IL (1) IL197297A0 (es)
MA (1) MA30767B1 (es)
MX (1) MX2009002625A (es)
NO (1) NO20091099L (es)
PE (1) PE20081368A1 (es)
TW (1) TW200826934A (es)
WO (1) WO2008031772A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031772A1 (en) 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
GB0716573D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Chemical compounds
GB0804326D0 (en) * 2008-03-07 2008-04-16 Glaxo Group Ltd Novel compounds
WO2010125033A1 (en) * 2009-04-29 2010-11-04 Glaxo Group Limited Azabicyclo[4.1.0]heptane derivatives
WO2010130672A1 (en) * 2009-05-12 2010-11-18 Glaxo Group Limited Azabicyclo [4.1.0] heptane derivatives and their use as monoamine reuptake inhibitors
WO2010133569A1 (en) * 2009-05-20 2010-11-25 Glaxo Group Limited Azabicyclo[4.1.0]heptane derivatives
WO2010146025A1 (en) * 2009-06-17 2010-12-23 Glaxo Group Limited Tricyclic azabicyclo [4.1.0] heptane derivatives as inhibitors of serotonin, dopamine and norepinephrine re-uptake
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
DE102011100831A1 (de) 2011-05-07 2012-11-08 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von GSK 1360707 und verwandter Verbindungen mit 6-Aryl-1-[(alkyloxy) alkyl]-3-azabicyclo[4.1.0]heptan Grundgerüst
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
AU672644B2 (en) * 1992-12-23 1996-10-10 Neurosearch A/S Aryl substituted heterocyclic compounds
JP3238414B2 (ja) * 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
US6180648B1 (en) 1997-04-07 2001-01-30 Biostream Therapeutics, Inc. Analogs of cocaine
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US20060173064A1 (en) 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005092885A1 (en) 2004-02-27 2005-10-06 Eli Lilly And Company 4-amino-piperidine derivatives as monoamine uptake inhibitors
WO2008031772A1 (en) 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake

Also Published As

Publication number Publication date
AR062737A1 (es) 2008-11-26
US20100035914A1 (en) 2010-02-11
CA2662538A1 (en) 2008-03-20
CL2007002619A1 (es) 2008-04-18
JP2010502761A (ja) 2010-01-28
JP4448198B2 (ja) 2010-04-07
US7691893B2 (en) 2010-04-06
MX2009002625A (es) 2009-03-24
CO6150149A2 (es) 2010-04-20
IL197297A0 (en) 2009-12-24
EA200970266A1 (ru) 2009-08-28
BRPI0716532A2 (pt) 2013-09-24
TW200826934A (en) 2008-07-01
PE20081368A1 (es) 2008-11-19
EP2064186A1 (en) 2009-06-03
WO2008031772A1 (en) 2008-03-20
KR20090064447A (ko) 2009-06-18
MA30767B1 (fr) 2009-10-01
US20080114049A1 (en) 2008-05-15
AU2007296301A1 (en) 2008-03-20
CR10671A (es) 2009-04-29

Similar Documents

Publication Publication Date Title
NO20091099L (no) Zabicykloforbindelser som inhibitorer av monoamingjenopptakelse
NO20080784L (no) Histondeacetylaseinhibitorer
BRPI0913457B8 (pt) Composto e composição farmacêutica
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
BRPI0818672B8 (pt) composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas
WO2012134203A3 (ko) 화합물 및 이를 이용한 유기전기소자, 그 전자장치
WO2007085451A3 (en) 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents
NO20044034L (no) ACC inhibitorer
BR112013004925A2 (pt) derivados de éster de fosfonato e métodos de síntese deles.
NO20091999L (no) MAPK/ERK kinase inhibitorer
BR112015026441A2 (pt) derivados de fulereno aperfeiçoados e materiais, métodos e dispositivos relacionados
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
BR112022003982A2 (pt) Compostos heterocíclicos
CO7461129A2 (es) Beta-glucosidasa de magnaporthe grisea
BRPI0811200A8 (pt) Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina
CY1113914T1 (el) Νεα παραγωγα διυδροϊνδολονων, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
BRPI0717775B8 (pt) preparação de estansoporfina de alta pureza em larga escala
CY1109637T1 (el) Νεα τρικυκλικα παραγωγα, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse
NO20101187L (no) Distribuerte sensorer for dynamisk modellering
EA200801884A1 (ru) Новый способ синтеза ранелата стронция и его гидратов
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CY1110944T1 (el) Νεα παραγωγα κυκλοαλκυλιωμενων βενζοθειαδιαζινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application